West Pharmaceutical Services (WST): The Hidden Pharma Giant Riding the GLP-1 Boom to a Potential Breakout

While household names like Eli Lilly (LLY) and Novo Nordisk (NVO) capture the headlines in the GLP-1 boom, a critical supplier sits quietly in the background, packaging and delivering the life-saving drugs. West Pharmaceutical Services (WST) is that behind-the-scenes giant, and after a brutal multi-year correction, fundamental and technical signals suggest it might be staging a major comeback.

The Fundamental Turnaround: From Covid Hangover to GLP-1 Tailwind
West Pharmaceutical manufactures the essential components—rubber stoppers, seals, plungers, and auto-injectors—that keep injectable drugs safe and functional. For years, the company struggled with the aftermath of the Covid vaccine boom. After peaking at $475 in September 2021, the stock entered a prolonged period of digestion as customers worked through excess inventory. Revenue stagnated at roughly $2.83 billion in 2021 compared to $2.89 billion in 2024, while diluted EPS fell from $8.67 to $6.69, and gross margins compressed from 41.5% to 34.5%.

The low point came on February 13, 2025, when West guided 2025 EPS to $6.00–$6.20—far below the $7.44 consensus. The stock plunged 38% in a single session, marking the worst day in the company’s history and capping a nearly 60% peak-to-trough drawdown.

However, the tide has turned. In the most recent quarter, sales grew 13.8% to $872 million, and adjusted EPS rose 28.8% to $2.37, beating estimates by $0.29. High-value components, specifically the premium stoppers and seals, grew 19.4% and now represent 49% of total sales, with GLP-1 drugs alone accounting for 18% of revenue. Gross margin expanded by 200 basis points to 37.7%.

Management has raised guidance twice this year, pushing sales expectations to between $3.345 billion and $3.38 billion, and projecting adjusted EPS of $8.85 to $9.05—a 21% to 24% growth rate. To bolster shareholder value, West sold its SmartDose 3.5mL injector business to AbbVie for $136 million, repurchased $454 million of stock in the first half of the year, and authorized a new $1 billion buyback program, representing roughly 4% of the current market capitalization. Additionally, the company welcomed Michel Lagarde as its new CEO in late August, succeeding Eric Green. Lagarde previously served as COO of Thermo Fisher, bringing deep industry experience to the corner office.

Technical Analysis: Setting Up for a Potential Breakout
From a technical perspective, the stock price action is reflecting this fundamental recovery. Shares are up 37% year-to-date and 45% over the past year, trading around $373—roughly 67% off its 52-week low of $223.83. At current levels, the stock trades at approximately 42x the midpoint of 2026 guidance, with earnings growing north of 20%. While not cheap, this valuation is well below the 55x multiple the stock commanded at its 2021 peak, and this time, the multiple is supported by rising earnings rather than rolling over.

The technical setup is highly constructive. After spending six months consolidating in a range between the mid-$220s and $290s, the stock broke out in late April, quickly followed by a golden cross where the 50-day moving average crossed above the 200-day. The rally carried shares to the mid-$360s by early July, followed by a brief pullback to the $325 area where buyers stepped in aggressively. Another test of the $330 level in early September saw immediate buying interest, demonstrating strong buyer tenacity.

Currently trading near $369, with the 50-day rising at $352 and the 200-day at $302, the stock is within striking distance of its summer high of $383. A weekly close above $383 would signal a fresh 52-week high and confirm a strong bullish breakout. The Relative Strength Index (RSI) sits at a healthy 59, leaving plenty of room for further upward momentum without entering overbought territory.

For traders, $50 serves as the key line in the sand, coinciding with the rising 50-day and the top of the August consolidation. A close below this level would suggest the rally has stalled. Longer-term investors can anchor to the $325–$330 support zone, which has held twice in the last 90 days. A weekly close below $325 would invalidate the bullish thesis and suggest that the buyers who defended that zone twice are finally giving up.

Source link